Previous 10 | Next 10 |
Guardant Health, Inc. (GH) Q1 2022 Earnings Conference Call May 05, 2022, 04:30 PM ET Company Participants Alex Kleban - VP, IR Helmy Eltoukhy - Co-CEO AmirAli Talasaz - Co- CEO Mike Bell - CFO Conference Call Participants Puneet Souda - SVB Securities Dan Arias - Stifel Jack Meehan - Nephron...
Q1 clinical and biopharma volumes up 47% and 45% year over year Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported fin...
Guardant Health (NASDAQ:GH) is scheduled to announce Q1 earnings results on Thursday, May 5, after market close. The consensus EPS estimate is -$1.10 (-124.5% Y/Y) and the consensus revenue estimate is $95.71M (+21.7% Y/Y). Over the last 2 years, GH has beaten EPS estimates 63% of the time an...
Highly sensitive Shield test offers convenient screening method that can be completed with simple blood draw, helping overcome barriers to compliance Test demonstrated sensitivity of 91% in colorectal cancer and 20% in advanced adenoma detection with specificity of 92% in va...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada. Guardant Health’s management is scheduled to participate in a fireside chat on T...
Guardant Health (NASDAQ: GH) creates blood tests that inform oncologists of possible treatment options for cancer. It also offers a battery of testing that can alert clinicians to disease recurrence. This is commonly referred to as a liquid biopsy, a blood draw that could potentiall...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A sharp spike in bond yields pressured growth stocks and ...
Amid a down market, Guardant shares are trading at a bargain to their estimated value. Meanwhile, Guardant continues to procure robust sales increases and narrowed its bottom line depreciation. The recent Epic deal for its diagnostics to reach over 250M patients is a transformativ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2022 after market close on Thursday, May 5, 2022. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m....
- Multi-Cancer Assay Highly Sensitive and Specific in Screening for Detection of Early-Stage Cancers, Able to Identify Tumor Tissue of Origin with High Accuracy Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new data demonstrating the a...
News, Short Squeeze, Breakout and More Instantly...
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...